|
|
| Pessoa,Luciana Santos; Vidal,Luãnna Liebscher; Costa,Emmerson C.B. da; Abreu,Celina Monteiro; Cunha,Rodrigo Delvecchio da; Valadão,Ana Luiza Chaves; Santos,André Felipe dos; Tanuri,Amilcar. |
| Abstract Approximately 185 million people worldwide are chronically infected with hepatitis C virus (HCV). The first-wave of approved NS3 protease inhibitors (PIs) were Telaprevir and Boceprevir, which are currently discontinued. Simeprevir is a second-wave PI incorporated into the Brazilian hepatitis C treatment protocol. Drug resistance plays a key role in patients' treatment regimen. Here, we developed a simple phenotypic assay to evaluate the impact of resistance mutations in HCV NS3 protease to PIs, using a protein expression vector containing wild type NS3 protease domain and NS4A co-factor. We analyzed the impact of five resistance mutations (T54A, V36M, V158I, V170I and T54S+V170I) against Telaprevir, Boceprevir and Simeprevir. Protein... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Protease inhibitor; Phenotypic test; Hepatitis C virus; HCV NS3 protease; Resistance mutation. |
| Ano: 2016 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572016000300358 |
| |
